A Phase 3 interventional study of Aripiprazole in Autistic Disorder, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 5 sites in Japan. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2024-08-06.
Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing aripiprazole in Autistic Disorder — none open to participants now, none under way, none of them phase 3. Aripiprazole · Autistic Disorder.
Among the 15 studies testing aripiprazole in Autistic Disorder, this one is the 7th largest by enrollment, is one of 2 that started in 2012, is one of 7 in phase 3, and was the 12th registered.
1,033 studies on the registry are indexed under Autistic Disorder; 269 are open to participants now.
Browse Autistic Disorder studies →None of the 15 studies testing aripiprazole in Autistic Disorder is open now. The open studies under Autistic Disorder, anywhere →
Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 183 Autistic Disorder studies recruiting now, 33 (18%) set no upper age limit and 143 (78%) stop at 75 or younger; 148 take children under 18; 56 take healthy volunteers.
This study: 6 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2012.
This study's enrollment of 86 is above the median of 49 across 813 interventional studies indexed under Autistic Disorder.
Median enrollment 81 across the 15 interventional studies. Of the 14 that completed or were terminated, 12 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 15 have an industry lead sponsor. The 10 most frequent:
This study is registered under Otsuka Pharmaceutical Co., Ltd., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.
11 studies in Autistic Disorder by Otsuka Holdings Co., Ltd.: none open now, none under way, none of them phase 3. Of 11 finished, 9 (82%) have results posted.
Among the 11 studies in Autistic Disorder by Otsuka Holdings Co., Ltd., this one is the 9th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2012, is one of 8 in phase 3, and was the 5th registered.
Otsuka Holdings Co., Ltd.’s Autistic Disorder studies by the year they started, since 2006.
None of the studies under way reaches primary completion within a year.
Among the 15 studies testing aripiprazole in Autistic Disorder, from their registry updates:
Among Otsuka Holdings Co., Ltd.’s 11 in Autistic Disorder:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to investigate the safety and efficacy of aripiprazole orally administered over long term in subjects who complete a short-term treatment study of pediatric Autistic Disorder (031-11-002 study).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
administered orally once daily
Drug: Aripiprazole
Flexibly dose administered orally once daily
Mean Change From Baseline at the Final Assessment in Aberrant Behavior Checklist Japanese Version (ABC-J) Irritability Subscale Score
The ABC-J Irritability subscale consists of 15 items. Each item scores range from 0 to 3: 0 = No problem, 1 = Mild aberrant behavior, 2 = Moderate aberrant behavior, and 3 = Severe aberrant behavior. Individual scores were summed, therefore, the overall score range was between 0-45. Higher scores represent worse condition.
Time frame: Baseline, the final administration
| Milestone | Aripiprazole |
|---|---|
| Started | 86 |
| Completed | 46 |
| Not completed | 40 |
| Withdrew: Adverse event | 10 |
| Withdrew: Physician decision | 16 |
| Withdrew: Protocol violation | 5 |
| Withdrew: Withdrawal by subject | 9 |
The ABC-J Irritability subscale consists of 15 items. Each item scores range from 0 to 3: 0 = No problem, 1 = Mild aberrant behavior, 2 = Moderate aberrant behavior, and 3 = Severe aberrant behavior. Individual scores were summed, therefore, the overall score range was between 0-45. Higher scores represent worse condition.
| units on a scale | Aripiprazole |
|---|---|
| Mean Change From Baseline at the Final Assessment in Aberrant Behavior Checklist Japanese Version (ABC-J) Irritability Subscale Score | -3.2 ± 8.1 |
Collected over From the start date of investigational medicinal product (IMP) administration to date of the final examination. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aripiprazole | — | 10/86 (11.6%) | 84/86 (97.7%) |
| Event | Aripiprazole |
|---|---|
| AutismNervous system disorders | 2/86 |
| Adenoidal hypertrophyRespiratory, thoracic and mediastinal disorders | 2/86 |
| MalaiseGeneral disorders | 1/86 |
| Lymphadenitis bacterialInfections and infestations | 1/86 |
| Hand fractureInjury, poisoning and procedural complications | 1/86 |
| Melanocytic naevusNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/86 |
| AgitationPsychiatric disorders | 1/86 |
| Glomerulonephritis acuteRenal and urinary disorders | 1/86 |
| Status asthmaticusRespiratory, thoracic and mediastinal disorders | 1/86 |
| Tonsillar hypertrophyRespiratory, thoracic and mediastinal disorders | 1/86 |
| Event | Aripiprazole |
|---|---|
| NasopharyngitisInfections and infestations | 53/86 |
| SomnolenceNervous system disorders | 28/86 |
| InfluenzaInfections and infestations | 25/86 |
| Weight increasedInvestigations | 21/86 |
| VomitingGastrointestinal disorders | 12/86 |
| GastroenteritisInfections and infestations | 10/86 |
| Increased appetiteMetabolism and nutrition disorders | 10/86 |
| Rhinitis allergicRespiratory, thoracic and mediastinal disorders | 9/86 |
| Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders | 9/86 |
| Dental cariesGastrointestinal disorders | 8/86 |
| Age, Categorical(Participants) | Aripiprazole |
|---|---|
| <=18 years | 86 |
| Between 18 and 65 years | 0 |
| >=65 years | 0 |
| Age, Continuous(years) | Aripiprazole |
|---|---|
| Mean | 10.0 ± 3.0 |
| Sex: Female, Male(Participants) | Aripiprazole |
|---|---|
| Female | 17 |
| Male | 69 |
| Region of Enrollment(participants) | Aripiprazole |
|---|---|
| Japan | 86 |
The record gives a start of Sep 2012, a primary completion of Oct 2016 and a completion of Oct 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2017, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aripiprazole
Otsuka Pharmaceutical Co., Ltd. →